A phase I trial of emavusertib (CA-4948) in combination with gemcitabine and nab-paclitaxel in metastatic or unresectable pancreatic ductal adenocarcinoma (PDAC). (ASCO 2026) - Apr 21, 2026 - Abstract #e16410; P1 | "At this early stage of the study, emavusertib in combination with G/nP as second-line therapy for metastatic or unresectable PDAC has a manageable toxicity profile and shows encouraging preliminary results with an ORR of 20% and DCR of 60%, compared to historical ORR of 13-17% and DCR of 46-58% for G/nP, respectively. Escalation to DL4 is ongoing, which will be followed by dose expansion at RP2D."
Combination therapy • Metastases • P1 data • Fibrosis • Hematological Disorders • Neutropenia • Oncology • Pancreatic Ductal Adenocarcinoma • IRAK4
|
|
Patrick Grierson; Farshid Dayyani; Susanna Ulahannan; Monica Patel; Mina Abdiannia; Amberly Brown; Kian-Huat Lim; Gulam Manji; Robert Lentz
|